LCS
LUCD icon

Levin Capital Strategies’s Lucid Diagnostics LUCD Stock Holding History

Levin Capital Strategies’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-66,528
Closed -$54.2K – 251
2024
Q3 		$54.2K Buy
+66,528
New +$54.5K 0.01% 220
2023
Q1 		– Sell
-36,799
Closed -$50K – 264
2022
Q4 		$50K Buy
+36,799
New +$66.2K 0.01% 230

Other funds holding LUCD

LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SS
Sunbelt Securities Houston, Texas $1.58B AUM 28.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Levin Capital Strategies's LUCD Position: Q4 2024 in Review

Levin Capital Strategies sold out of Lucid Diagnostics (LUCD) in Q4 2024, closing a stake of 66,528 shares — an estimated $54.2K sold.

Levin Capital Strategies first reported a position in LUCD in Q4 2022 and held it in 2 quarters. The position peaked at $54.2K in Q3 2024. 33 funds tracked by Wall St. Rank hold LUCD as of Q4 2024.

  • Levin Capital Strategies reported no remaining Lucid Diagnostics position as of Q4 2024 after selling out during the quarter.
  • Levin Capital Strategies sold 66,528 Lucid Diagnostics shares in Q4 2024, an estimated $54.2K.
  • Levin Capital Strategies first reported a position in Lucid Diagnostics in Q4 2022 and held it in 2 quarters.
  • Levin Capital Strategies's Lucid Diagnostics position peaked at $54.2K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q4 2024.

Based on Levin Capital Strategies's 13F filing for Q4 2024, filed 5 Feb 2025.